Single award · contract

Overall Objective of This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of…

Award ID: 75A50121C00077

FY2021 · complete year · data as of 2026-07-12

A single federal award, with both ends of the trail linked.

$95.6M
Total award value

Award 75A50121C00077 is a contract from the Department of Health and Human Services, $95.6M obligated, FY2021 to FY2029, for Overall Objective of This Contract Is to Advance the Development of Monovalent Vaccines for…. The work is performed in New York. It is classified as NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)) and PSC AN42 (Health R&D Services; Health Care - Other; Applied Research). Source

Description

The Overall Objective of This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (MARV) and Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based on Recombinant Expression of Filovirus Glycoproteins in

Award details

Award typeContract
PIID75A50121C00077
Action date2021
Period87 mo
RecipientOutside our Phase 1 contractor set: see methodology
Place of performanceNew York →
Competed?Not recordedSource
Total (exact)$95,592,504

More from Department of Health and Human Services

Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.